GCTK insider filings
Glucotrack, Inc. — 15 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2025-10-07. Screen GCTK transaction legs live →
Insider transaction summary — last 90 days
No insider filings (Forms 3/4/5) for GCTK between 2026-07-10 and 2026-10-08. The table below lists the most recent filings on record.
Recent insider filings — Glucotrack, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2025-10-07 | 4 | Carter Erin Catherine — Director | Grant/award (A): 32 @ $0 · Grant/award (A): 1,000 @ $0 · Grant/award (A): 386 @ $0 · Grant/award (A): 4,055 (derivative) @ $0 | EDGAR |
| 2025-10-07 | 4 | Goode Paul — Chief Executive Officer, Director | Other (J): 42 | EDGAR |
| 2025-10-07 | 4 | Malave Luis — Director | Grant/award (A): 35 @ $0 · Grant/award (A): 1,200 @ $0 · Grant/award (A): 463 @ $0 · Grant/award (A): 4,055 (derivative) @ $0 | EDGAR |
| 2025-10-07 | 4 | Balo Andrew K — Director | Grant/award (A): 75 @ $0 · Grant/award (A): 3,332 @ $0 · Grant/award (A): 1,285 @ $0 · Grant/award (A): 4,055 (derivative) @ $0 | EDGAR |
| 2025-03-31 | 4 | John A. Ballantyne Revocable Living Trust dated 08/01/2017 — 10% owner | Other (J): 132,036 @ $31 · Option exercise/expiry (X): 2,560,553 @ $0 · Purchase (P): 106,667 (derivative) · Purchase (P): 76,191 (derivative) · Purchase (P): 59,260 (derivative) · Grant/award (A): 132,036 (derivative) · +2 more | EDGAR |
| 2025-03-31 | 4 | BALLANTYNE JOHN — Director, 10% owner | Other (J): 132,036 @ $31 · Option exercise/expiry (X): 2,560,553 @ $0 · Grant/award (A): 4,126 @ $0 · Purchase (P): 106,667 (derivative) · Purchase (P): 76,191 (derivative) · Purchase (P): 59,260 (derivative) · +3 more | EDGAR |
| 2025-03-31 | 4 | Carter Erin Catherine — Director | Grant/award (A): 903 @ $0 · Grant/award (A): 458 @ $0 · Conversion (C): 2,078 @ $31.20 · Option exercise/expiry (X): 40,297 @ $0 · Grant/award (A): 1,896 @ $0 · Purchase (P) @ $50,000 · +4 more | EDGAR |
| 2025-03-31 | 4 | Malave Luis — Director | Grant/award (A): 8 @ $0 · Grant/award (A): 11 @ $0 · Grant/award (A): 25 @ $0 · Grant/award (A): 34 @ $0 · Grant/award (A): 44 @ $0 · Grant/award (A): 29 @ $0 · +11 more | EDGAR |
| 2025-03-28 | 4 | Goode Paul — Chief Executive Officer, Director | Conversion (C): 796 @ $31.20 · Other (J): 1,500 · Option exercise/expiry (X): 15,435 @ $0 · Grant/award (A): 3,277 (derivative) @ $0 · Purchase (P): 2,100 (derivative) · Purchase (P) @ $10,000 · +4 more | EDGAR |
| 2025-03-28 | 4 | Danzig Allen — Director | Grant/award (A): 44 @ $0 · Grant/award (A): 229 @ $0 · Grant/award (A): 1,498 @ $0 | EDGAR |
| 2025-03-28 | 4 | Fischell Robert — Director | Grant/award (A): 318 @ $0 · Grant/award (A): 229 @ $0 · Grant/award (A): 1,498 @ $0 | EDGAR |
| 2025-03-28 | 4 | Balo Andrew K — Director | Grant/award (A): 4,490 @ $0 | EDGAR |
| 2024-07-03 | 4 | Goode Paul — Chief Executive Officer | Purchase (P): 42,000 (derivative) | EDGAR |
| 2024-07-03 | 4 | SYCOFF DREW — Director, 10% owner | Purchase (P): 138,000 (derivative) | EDGAR |
| 2024-04-24 | 4 | SYCOFF DREW — Director, 10% owner | Purchase (P): 182,539.60 @ $1.26 | EDGAR |
Recent 8-K events — Glucotrack, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-09-28 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-09-24 | 8-K | 1.01 — Entry into a Material Definitive Agreement 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-09-23 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-09-18 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-09-14 | 8-K | 1.01 — Entry into a Material Definitive Agreement 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-09-11 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant 3.02 — Unregistered Sales of Equity Securities 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-09-09 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant 3.02 — Unregistered Sales of Equity Securities | EDGAR |
| 2026-08-28 | 8-K/A | 2.01 — Completion of Acquisition or Disposition of Assets 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-28 | 8-K | 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-27 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
Registration filings — Glucotrack, Inc.
Securities Act registration lifecycles tracked for this issuer (live-forward since 2026-08-01), threaded by SEC file number.
- SEC file 333-299000 (S-1) — latest: Initial registration (S-1), filed 2026-09-18
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=GCTK returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →